IDT Biologika
Dedicated to Contract Development and Manufacturing of
Viral Vaccines, Viral Vectors and Biologics

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing including drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilities meeting EMA, FDA and ANVISA standards.

We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.

Our Awards

CMO Leadership Award 2021

Service

CMO Leadership Award 2021

Reliability

PharmaTech Outlook

2020

Focus Innovation Award

2020

Twitter
@IDT Biologika

Thursday, 21. January 2021

IDT Biologika received two of Outsourced Pharma and Life Science Leader’s CMO Leadership Awards 2021 in the categor… https://t.co/ImYRunraKV more info

Friday, 15. January 2021

“Never again 2020: Let’s get vaccinated.” This is the motto of the German campaign “Initiative against Corona” to i… https://t.co/E3TpZK57tX more info

Monday, 21. December 2020

Merry Christmas and a Happy New Year 2021 from IDT Biologika https://t.co/UGj5goXfpa more info

Thursday, 17. December 2020

We are also delighted to welcome Thomas Genova to the Business Development team at IDT Biologika. As with his colle… https://t.co/hV3jLgoVfx more info

Thursday, 10. December 2020

We are proud to have successfully recruited Christian Ahlmark for our Business Development team. As Senior Director… https://t.co/dDzt7ERKoO more info

Thursday, 3. December 2020

We have recruited three employees with great pharmaceutical expertise for our Business Development team. One of the… https://t.co/Q6jRGGp50y more info

Tuesday, 24. November 2020

Federal Minister @jensspahn, who visited IDT Biologika together with Prime Minister @reinerhaseloff, praised the pe… https://t.co/SemdJX9hYA more info

Monday, 23. November 2020

RT @BMG_Bund: Die deutsche Firma @idtbiologika forscht an einem Corona-Impfstoff, der - wenn alles gut geht - nächstes Jahr auf dem Markt k… more info

Monday, 23. November 2020

RT @BMG_Bund: "Ich bin überzeugt, wenn wir gemeinsam diesen schwierigen Corona-Winter hinter uns gebracht haben, wird auch die Bereitschaft… more info

Start of second study phase of vector vaccine against COVID-19 postponed

Monday, 11. January 2021

Initial data for corona vaccine indicate good tolerability but weak immune response more info

Federal Minister of Health visits IDT Biologika

Tuesday, 24. November 2020

5 million vaccine doses against COVID-19 more info

IDT Biologika receives official notification of funding from the Federal government

Thursday, 8. October 2020

IDT Biologika receives official notification of funding from the Federal government more info

SARS-CoV-2: IDT Biologika fills vaccine candidate

Wednesday, 29. July 2020

Clinical phase about to begin more info

Deputy leader of the parliamentary FDP visits IDT Biologika

Friday, 10. July 2020

Battle against SARS-CoV-2 at the heart of Germany more info